CYPH - Cypherpunk Technologies Inc. News

Sectors

CYPH

Cypherpunk Technologies Inc.

0.67

1 x 0.65

10 x 0.69

bid

ask

0.07

9.04%

10 @ 07:59 PM

0.68 +0.01 (1.16%)

Ytd	-42.05%
1y	-61.81%

0.67

day range

0.72

0.23

52 week range

3.70

Open	0.69	Prev Close	0.74	Low	0.67	High	0.72	Mkt Cap	38.24M
Vol	1.57M	Avg Vol	4.70M	EPS	-1.17	P/E	-0.58	Forward P/E	N/A
Beta	0.07	Short Ratio	N/A	Inst. Own	N/A	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-13	50-d Avg	0.85	200-d Avg	0.91	1yr Est	0.00

CYPH News

benzinga.com

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 40.9% to $0.16 during Thursday's pre-

benzinga.com

Cantor Fitzgerald Initiates Coverage On Cypherpunk Technologies with Overweight Rating, Announces Pr

Cantor Fitzgerald analyst Gareth Gacetta initiates coverage on Cypherpunk Technologies (NASDAQ:CY

seekingalpha.com

Cypherpunk Technologies Inc. (CYPH) Shareholder/Analyst Call Prepared Remarks Transcript

benzinga.com

12 Health Care Stocks Moving In Monday's Intraday Session

benzinga.com

10 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Monday's Intraday Session

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com

12 Health Care Stocks Moving In Friday's Pre-Market Session

benzinga.com

Why Solidion Technology Shares Are Rallying Over 50%; Here Are 20 Stocks Moving Premarket

Solidion Technology, Inc. (NASDAQ: STI) rose 50.55% in pre-market trading on Friday after announcing

prnewswire.com

Cypherpunk Technologies Reports First Quarter 2026 Financial Results

CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypher

benzinga.com

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

prnewswire.com

Cypherpunk Increases its Zcash Stake, Launches New Website and Investor Dashboard

CAMBRIDGE, Mass., April 15, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc., (Nasdaq: CYPH) today

benzinga.com

9 Health Care Stocks Moving In Wednesday's Pre-Market Session

prnewswire.com

Cypherpunk Reports Full Year 2025 Financial Results

CAMBRIDGE, Mass., March 16, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cyph

prnewswire.com

Cypherpunk Makes $5M Investment into Zcash Open Development Lab (ZODL)

Cypherpunk expands its holdings with new $5M investment in Zcash company, ZODL, alongside key invest

benzinga.com

12 Health Care Stocks Moving In Wednesday's After-Market Session

benzinga.com

12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com

12 Health Care Stocks Moving In Thursday's After-Market Session

benzinga.com

12 Health Care Stocks Moving In Tuesday's After-Market Session

prnewswire.com

Cypherpunk Adds Arjun Khemani as Strategic Advisor

CAMBRIDGE, Mass., Jan. 22, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) ("Cypher

prnewswire.com

Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC

CAMBRIDGE, Mass., Dec. 30, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) ("Cypher

benzinga.com

Why Bolt Projects Holdings Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarke

prnewswire.com

Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor

CAMBRIDGE, Mass. , Dec. 19, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) today a

seekingalpha.com

Cypherpunk Technologies Inc. (CYPH) Leap Therapeutics, Inc. - Shareholder/Analyst Call Prepared Rema

prnewswire.com

Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor

CAMBRIDGE, Mass. , Dec. 9, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) today an

benzinga.com

12 Health Care Stocks Moving In Tuesday's Intraday Session

benzinga.com

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

prnewswire.com

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

CAMBRIDGE, Mass. , Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as L

prnewswire.com

Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strate

Khing Oei appointed Chairman of the Board; Will McEvoy appointed Chief Investment Officer and Member

prnewswire.com

Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population

prnewswire.com

Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Ca

CAMBRIDGE, Mass. , Oct. 9, 2025 /PRNewswire/ -- Leap Therapeutics (Nasdaq:LPTX), a biotechnology com

prnewswire.com

Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss C

CAMBRIDGE, Mass. , Oct. 6, 2025 /PRNewswire/ -- Leap Therapeutics (Nasdaq:LPTX), a biotechnology com

prnewswire.com

Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congr

CAMBRIDGE, Mass. , Sept. 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechn

prnewswire.com

Leap Therapeutics Reports Second Quarter 2025 Financial Results

CAMBRIDGE, Mass. , Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnol

prnewswire.com

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announc

Updated data from DeFianCe study continue to demonstrate statistically significant improvements in P

prnewswire.com

Leap Therapeutics Reports First Quarter 2025 Financial Results

CAMBRIDGE, Mass. , May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnolo

prnewswire.com

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at th

FL-501 fully restored body composition and reversed key indicators of cachexia in preclinical models